Overview of the Tolerability of Gefitinib (IRESSA) Monotherapy: Clinical Experience in Non-Small-Cell Lung Cancer

Author： Beverley Forsythe Karen Faulkner

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.14, 2004-01, pp. : 1081-1092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E. Easthope Stephanie E.

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Gefitinib in non-small cell lung cancer

By Tamura Kenji Fukuoka Masahiro

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 985-993

Informa Healthcare

Access to resources Recommend Favorite

Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3689-3700

Bentham Science Publishers

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Gefitinib: A Review of its Use in the Management of Advanced Non-Small-Cell Lung Cancer

By James E. Frampton Stephanie E. Easthope

Drugs, Vol. 64, Iss. 21, 2004-01 ,pp. : 2475-2492

Adis International

Access to resources Recommend Favorite